Side-by-side · Research reference

TeriparatidevsThymalin

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AFDA-ApprovedHUMAN-REVIEWED10/62 cited

BHuman-MechanisticAUTO-DRAFTED12/40 cited

Teriparatide

PTH (1-34) Fragment · FDA-Approved

20 mcgDaily dose

12-18 moAnabolic windowFerrari 2026

SQRoute

SQ · Thigh/Abdomen · Once Daily

Thymalin

Immune restorer · Russian peptide bioregulator

5–10 mgPer cycle doseKhavinson 2002

HumanMechanisticKhavinson 2002

HoursHalf-life (est)

IM · Daily for 5–10 days · 1-2×/year

01Mechanism of Action

Parameter

Teriparatide

Thymalin

Primary target

Parathyroid hormone 1 receptor (PTH1R) on osteoblastsXue 2026

T-cell precursors + thymus-axis maturation pathwayKhavinson 2002

Pathway

PTH1R activation → cAMP/PKA signaling → osteoblast differentiation and activity

Modulation of T-cell differentiation + thymic hormone restoration in age-involuted thymusKhavinson 2002

Downstream effect

Stimulates osteoblast formation and bone matrix deposition; increases bone mineral density at trabecular and cortical sites

Restored T-cell populations, improved immune surveillance, reduced infection rates in elderlyKhavinson 2002

Feedback intact?

Yes — intermittent dosing preserves anabolic effect; continuous exposure causes catabolic bone resorption

—

Origin

Recombinant 34-amino-acid N-terminal fragment of 84-amino-acid human PTH

Polypeptide fraction isolated from calf thymus extractKhavinson 2002

Antibody development

—

02Dosage Protocols

Parameter

Teriparatide

Thymalin

Standard dose (osteoporosis)

20 mcg / day

FDA-approved regimen for severe osteoporosis.

—

Frequency

Once daily

Intermittent administration preserves anabolic effect.

Once daily during cycle

Maximum duration

24 months lifetime

Anabolic effect wanes after 12-18 months; FDA recommends max 2-year cumulative exposure.

—

Hypoparathyroidism dose

20 mcg / day

Used off-label for chronic hypoparathyroidism.

—

Evidence basis

RCT / FDA-approved

Russian clinical + in vitroKhavinson 2002

Pelvic fragility fractures

20 mcg / day × 8-12 weeks

Accelerates fracture healing; reduces time to union.Crooks 2026

—

Route

Subcutaneous (thigh or abdomen)

—

Timing

Morning or evening (flexible)

Morning preferred

Storage

Refrigerate 2-8 °C; pen device stable at room temp for 28 days after first use

—

Pharmacogenetics

ALDH2 polymorphisms may influence BMD responseObara 2026

ALDH2*2 variant carriers show altered PTH receptor expression.Obara 2026

—

Standard dose

—

5–10 mg / day IM × 5–10 daysKhavinson 2002

Lower / starter dose

—

2.5 mg / day

Duration

—

5–10 day cycles, 1–2× per year

Reconstitution

—

Saline or bacteriostatic water

Half-life

—

Hours (estimated)

03Metabolic / Fat Loss Evidence

Parameter

Teriparatide

Thymalin

Fat loss application

None — teriparatide is a bone anabolic agent without direct lipolytic activity

—

04Side Effects & Safety

Parameter

Teriparatide

Thymalin

Hypercalcemia

Transient serum calcium elevation 4-6 hours post-injection

Monitor serum calcium; usually asymptomatic.

—

Orthostatic hypotension

Dizziness, lightheadedness within hours of injection

—

Nausea

Common, usually mild and transient

—

Leg cramps / Arthralgia

Musculoskeletal pain reported in clinical trials

—

Hypercalciuria

Increased urinary calcium excretion; monitor for nephrolithiasis risk

—

Osteosarcoma (black box warning)

Rat studies showed dose-dependent osteosarcoma; not observed in humans to date; contraindicated in Paget's disease, skeletal malignancy, prior radiation

—

Injection site reaction

Erythema, bruising, pain (uncommon)

Mild erythema at IM site

Allergic reaction

—

Rare hypersensitivity to bovine-derived polypeptide

Autoimmune flare

—

Theoretical risk in active autoimmune disease

Long-term safety

—

Limited Western data

Pregnancy / OB

—

Avoid

Absolute Contraindications

Teriparatide

·Paget's disease of bone (increased baseline osteosarcoma risk)
·Unexplained elevated alkaline phosphatase
·Prior skeletal radiation therapy
·Skeletal malignancies or bone metastases
·Hypercalcemic disorders (primary hyperparathyroidism)
·Pregnancy / lactation

Thymalin

·Pregnancy / breastfeeding
·Bovine protein hypersensitivity

Relative Contraindications

Teriparatide

·Active or recent nephrolithiasis
·Severe renal impairment (CKD G4-G5)
·Hypercalciuria without adequate monitoring

Thymalin

·Active autoimmune disease
·Concurrent immunosuppressant therapy

05Administration Protocol

Parameter

Teriparatide

Thymalin

1. Device preparation

Teriparatide is supplied in pre-filled pen injectors (Forteo pen). Store refrigerated at 2-8 °C until first use. After first injection, pen may be kept at room temperature for up to 28 days. Do not freeze.

Add 1–2 mL saline or bacteriostatic water per 10 mg vial.

2. Injection site

Subcutaneous injection into thigh or lower abdomen. Rotate sites daily to avoid lipodystrophy. Avoid areas with scars, bruises, or active skin conditions.

Intramuscular — deltoid or gluteal. Rotate sites.

3. Timing

Once daily, at approximately the same time each day. Morning or evening administration is acceptable. Take while sitting or lying down to minimize orthostatic hypotension risk.

Morning preferred during cycle.

4. Injection technique

Clean injection site with alcohol swab. Pinch skin, insert needle at 90° angle, and inject full dose (20 mcg). Hold for 5 seconds before withdrawing needle. Do not rub injection site.

Lyophilised: refrigerate, light-protected. Reconstituted: use immediately.

5. Monitoring

Baseline and periodic monitoring of serum calcium, urinary calcium, serum PTH (if hypoparathyroidism), and bone mineral density (DXA scan). Monitor for hypercalcemia 4-6 hours post-dose if symptomatic.

23–25G, 25–38 mm IM needle.

6. Calcium and vitamin D supplementation

Ensure adequate calcium (1000-1200 mg/day) and vitamin D (800-1000 IU/day) intake unless contraindicated by hypercalcemia or hypercalciuria.

—

06Stack Synergy

Teriparatide

— no documented stacks

Thymalin

+ Thymosin α-1

Moderate

View Thymosin α-1 →

Thymalin is a polypeptide complex; Thymosin α-1 is a single purified peptide. Both target the thymus-axis but at different levels — Thymalin restores broad thymic signaling; Tα-1 provides a specific molecular activator. Anecdotally combined for elderly immune support.

Thymalin: 5–10 mg IM · daily × 7 days
Thymosin α-1: 1.6 mg SQ · 2× weekly during the cycle
Primary benefit: Broad thymic restoration + targeted immune activation

Khavinson 2002 Camerini 2001